Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-149-7_3

Chapter 3: Overcoming the Blood-Brain Barrier (BBB): Role of Nanocarriers in Targeted Drug Delivery

Shivani Pannu[1], Ritu[1], Anish Sarswa[2], Rajni[3], Neha Sharma[4], Sonali Mishra[5], Puja Kumari[6], Puja Gulati[1*]

[1]*School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India.*
[2]*MM College of Pharmacy, MMDU, India.*
[3]*Faculty of Pharmaceutical Sciences, DAV University, Jalandhar, Punjab, India.*
[4]*DPER, BPSMV, Bhainswal Kalan, Sonipat, Haryana, India.*
[5]*Department of Pharmacognosy, Sai Nath University, Ranchi, India*
[6]*Department of BNYS, Jagannath University, Jaipur, Rajasthan, India.*
Corresponding Author
Dr. Puja Gulati
Email: puja_dugga@yahoo.co.in

Abstract

An important physiological barrier that protects the central nervous system (CNS) is the blood-brain barrier (BBB), which drastically limits access of therapeutic compounds to the brain. Neurological diseases such as Alzheimer's disease, Parkinson's disease, and brain tumors are very challenging due to the fact that nearly all of the large molecule drugs and greater than 98 percent of the small molecule drugs cannot pass through the blood-brain barrier. Nanocarrier-based drug delivery mechanisms can overcome this roadblock in a revolutionary manner. Drug solubility, stability, and selective delivery across the brain barrier are enhanced by numerous nanocarriers, to mention a few, liposomes, polymeric nanoparticles, dendrimers, micelles, and solid lipid nanoparticles. Methods, such as chemical modification, receptor-mediated transport, and the use of extrinsic stimuli (e.g., magnetic fields or ultrasound), have been shown to be promising for increasing the permeability of the BBB. Also, biomimetic designs, in combination with smart, stimuli-responsive nanocarriers, make it possible to achieve Site-specific and regulated medication release. The emerging technologies, such as the BBB-on-a-chip models and artificial intelligence, assist in the prediction accuracy and translatability in nanocarrier design. The potential benefits of nanotechnology are immense in terms of promoting CNS medicines but this potential comes with the hurdles that are drug toxicity, scaling, and regulation.

Keywords: *Blood-brain barrier, nanocarriers, liposomes, smart nanocarriers, personalized nanomedicine, neuropharmacology.*

1. Introduction

The brain, the central organ of the human nervous system, is protected by a highly selective, semipermeable structure known as the blood-brain barrier (BBB). This protective measure is vital in maintaining brain homeostasis, as it prevents dangerous materials and infections from entering the brain. However, it cannot be easily administered to treat central nervous system (CNS) disorders(1). Multiple sclerosis, epilepsy, Parkinson's disease, Alzheimer's disease, and brain malignancies, among others, will require drugs that target specific neurons(2). Nonetheless, around 100 percent of the large molecule therapies, as well as above 98 percent of the small-molecule medicines, cannot pass the blood-brain barrier (BBB) adequately, substantially compromising their efficacy. The endothelial cells forming the blood-brain-barrier (BBB) are aided by pericytes and astrocytic end-feet and are linked to each other through tight junctions(3). These complexes regulate the transportation of ions, molecules, and cells both to and within the brain via the blood and are a physical, as well as a metabolic barrier. Although this system is essential in the safeguard of the nervous system, the system becomes a major challenge in the pharmacological interventions(4). The traditional methods, such as intracerebral administration or high-dose systemic delivery, are invasive, non-specific, and are often associated with systemic toxicity. In neuropharmacology, the development of bespoke drug delivery systems, in this case, nanocarriers, has revolutionized the field(5). Such nano-platforms may be employed to encapsulate the drugs, protect them against degradation, change surface properties to enhance the selectivity of targets, and pass the BBB of the brain. Experiments and studies such as transient disruption of blood-brain barrier (BBB), carrier-mediated mechanisms, and receptor-mediated transportation are under work to find effective methods of transporting medicines across the barrier. Since the drug delivery techniques of the past have limitations, there is a pressing need to develop a novel delivery technique that can overcome the barrier of the blood-brain barrier (BBB) and gain access to the brain(6). The chapter explores with a focus on the processes, design factors, and translational potential of the delivery of nanocarriers to specific components of the brain, with a view to enhancing drug delivery.

2. Structure and Function of the Blood-Brain Barrier

Anatomy of the BBB

The blood-brain barrier (BBB) is a dynamic and highly selective blood-to-brain and brain-to-blood interface. Among them, our brain microvascular endothelial cells (BMECs) are connected together through intricate multi-junctional tight junctions that prevent paracellular transport(7). Astrocyte end-feet cells, pericytes, basement membrane, and adjacent neuronal and microglial cells provide support to these endothelial cells, completing the neurovascular unit (NVU). This structural integrity is

essential in order to maintain CNS homeostasis and to ensure there is a regulated milieu within which the neurons can operate. Figure 3.1



Figure 3.1: Schematic representation of the Blood-Brain Barrier (BBB) and its cellular components, including endothelial cells with tight junctions, pericytes, astrocyte end-feet, and the basement membrane. Arrows indicate possible drug transport pathways across the BBB.

Physiological Role

The primary physiological purpose of the BBB is to control the migration of ions, nutrients, and cells into the blood and the brain. It allows a selective influx of essential substances such as glucose, amino acids, and oxygen, in addition to protecting the central nervous system against hazardous xenobiotics, poisons, and infections(8). This regulation is carried out by special transporters, like the glucose transporter-1 (GLUT1) and other ATP-binding cassette (ABC) efflux transporters, especially P-glycoprotein (P-gp), which actively extrudes extracellular poisons and medications in the central nervous system(9). The BBB also serves as a crucial regulator in regulating immunological surveillance and neuroinflammation to maintain a constant internal surrounding required for the survival of healthy neurons and neurological transport(10).

Mechanisms of Selectivity and Restriction

The blood–brain barrier (BBB) primarily inhibits the entry of chemicals through strong intercellular bonds that tightly restrict paracellular diffusion. Examples of efflux transporters that actively eliminate lipophilic medications back into the bloodstream include P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP)(11). In addition to these transport mechanisms, enzymatic protections within the BBB degrade neurotoxic agents, further contributing to its defensive role. Moreover, limited transcytosis minimizes nonspecific vesicular trafficking.(4). Due to these mechanisms, the development of therapies targeting the central nervous system remains exceptionally challenging, permitting passage only to molecules with specific physicochemical properties such as minuscule size, lipophilicity, or ligand-mediated transport.(12).

Pathological Changes in BBB

The BBB can also be compromised under pathological conditions due to which may lead to enhanced permeability and subsequently cause an aberration of brain homeostasis. The often-associated conditions with the disruption of the blood-brain barrier, typified by the breakdown of tight junctions, the overexpression of inflammatory cytokines, and impairment of transport systems, are Alzheimer's disease, Parkinson's disease, multiple sclerosis, brain tumor, stroke, and traumatic brain injury.(13). These changes can aggravate the disease outcome because they allow immune cells and neurotoxic chemicals that invade the brain parenchyma to do so without detection. To create therapeutic means that will be able to overcome or temporarily modify the selective nature of the BBB, it will be necessary to have knowledge of both the structural and functional dynamics of this important barrier.(14). One potential way through which drugs can be delivered safely to the brain in a localized safely would be through the utilization of nanocarriers.(15).

3. Strategies to Overcome the BBB

The impermeability of the blood-brain barrier (BBB) is one of the greatest obstacles to the administration of therapies to the central nervous system (CNS)(16). Theorists have devised numerous mechanisms of enhancing medication delivery to the other side of this barrier, ranging from the highly specific receptor-holding devices to the intrusive application of those methods.(15). The effectiveness, mechanism, safety, and clinical applicability of every strategy vary. An overview of these old and innovative BBB penetration tricks can be found in Table 1.

Invasive Methods

Biochemical Modifications

A non-invasive alternative is chemically modifying medicine molecules so that they have a higher probability of permeating the blood-brain barrier(17). The way most frequently used to improve passive diffusion is the increase in lipophilicity of the drug to facilitate diffusion across endothelial membranes. Conversely, uncontrolled lipophilicity may lead to systemic toxicity and non-discriminatory distribution(18). Another trick of the biological trade is conjugating the drugs to carrier molecules such as peptides, amino acids, or minute molecular ligands that mimic the natural substrates of BBB transporters. As an example, a drug may utilize carrier-mediated transport (CMT) through coupling to glucose or leucine. Even though these changes augment bioavailability, often a trade-off must be made between metabolic stability, solubility, and molecular size(19).

Receptor-Mediated Transport (RMT)

RMT is one of the most promising non-invasive and targeted BBB penetration methods. This is the utilization of intrinsic receptors like low-density protein receptors (LDLR), insulin receptors, and transferrin receptors (TfR), which are present on the endothelial cells of the brain(20). The ligands or antibodies that are conjugated with drugs or drug-loaded nanocarriers specifically bind these receptors, and receptor-mediated endocytosis and transcytosis lead to entry of these drugs into the brain. An example is transferrin-modified liposomes and nanoparticles, which are substantially effective in delivering neuroprotective agents and anticancer drugs via the blood-brain barrier. The advantages of this practice are high specificity, reduced peripheral toxicity, and the option of recurring dosing. The problem of competition with endogenous ligands and potential saturation of the receptor, though, remains to be ironed out(21).

Focused Ultrasound and Magnetic Fields

Non-destructive techniques such as focused ultrasound (FUS) may provisionally and non-surgically destroy the blood-brain barrier in certain spots of the brain, especially when used together with microbubbles(22). FUS also enhances endothelial permeability via the mechanical stress of the vascular wall, and so allows the injection into the brain of drugs or nanocarriers without being exposed to the systemic circulation(23). This strategy to treat Alzheimer's disease and brain tumors is already under early clinical trials. Similarly, magnetic targeting passes the blood-brain barrier and accumulates in specific parts of the brain in a process that depends on the use of magnetically sensitive nanoparticles, which are guided by applied outside magnetic fields(24). Even though it requires certain equipment and further modification to be applied in human medicine,

the technology will enable us to control the localization of medications and the dosage in real-time.(17). Table 3.1

Table 3.1: Summary of Key Strategies to Overcome the BBB

Strategy	Mechanism	Key Advantage	Limitation
Invasive Methods	Direct brain injection, osmotic opening	High brain drug levels	Risky and not suitable long term
Biochemical Modifications	Lipophilic or transporter-mimicking drugs	Easy to apply, non-invasive	May cause off-target effects
CMT	Uses nutrient transporters	Leverages natural uptake	Limited drug types, saturation risk
RMT	Targets receptors (e.g., TfR, LDLR)	High specificity, non-invasive	Receptor competition, costly
Focused Ultrasound	Temporarily opens BBB with sound	Localized, reversible	Needs imaging & precision
Magnetic Targeting	Magnetic nanoparticles + field	Controlled, site-specific	Equipment-heavy, experimental

4. Introduction to Nanocarriers in CNS Drug Delivery

Nanocarriers are one of the revolutionary ways of overcoming the limitations of traditional drug administration to the central nervous system (CNS). Grains of therapeutic drugs to brain tissues remain a challenging undertaking due to the defensive character of the blood-brain barrier (BBB)(25). Nanocarriers Engineered materials at the nanoscale (1 1000 nm) offer a potential solution to enhance the solubility of the drug, the drug stability, bioavailability, and targeted site delivery through the blood-brain barrier.(26).

Types of Nanocarriers

Multiple types of nanocarriers have been developed and optimised for use in CNS applications that carry special structural properties and advantages:

Liposomes: These spherical membrane vesicles, created of phospholipid bilayers, can encapsulate both hydrophilic and lipophilic drugs(16). They can be used perfectly in BBB penetration due to their biocompatibility, a potential ability to fuse with cell membranes, and a possibility to be surface modified.

Polymeric Nanoparticles: These solid colloidal particles are made out of poly(lactic-co-glycolic acid) (PLGA) and other biodegradable polymers. They are able to be modified with ligands to enhance receptor-mediated entry across the blood-brain barrier and to allow control over drugs and a sustained release.(27).

Dendrimers: tree-like synthetic polymers that have one nonglobular core upon which there are a lot of branches. They give precise drug loading and functionalization due to their predictable structure. The CNS specificity could be enhanced by causing the dendrimers to be specific to a receptor.(28).

Solid Lipid Nanoparticles (SLNs): SLNs are an amalgamation of liposomes and polymeric nanoparticles, in that these lipids are stabilized using surfactants. They are especially useful in avoiding the deterioration of the drugs and in effecting controlled release of the drugs.(28).

Micelles: Self-assembling amphiphilic nanocarriers occur in aqueous environments. They may be adjusted with PEGylation or aimed ligands to cross the BBB, and they are excellent in those medications that are barely soluble.Figure.2



Figure 3.2: Classification of Nanocarriers Used in CNS Drug Delivery

Advantages of Nanocarriers for Brain Delivery

Nanocarriers possess the following benefits when it comes to the administration of CNS medication:

Enhanced BBB Permeation: BBB penetration via adsorptive or receptor-mediated transport is enabled by a surface modification (e.g., PEGylation or ligand conjugation).

Targeted Delivery: targeted delivery of the nanocarriers could be achieved by functionalizing them so nanocarriers readily accumulate in brain regions or at the site of a disease(29).

Controlled Release and Sustained Release: Controlled unreleasing or stimulus-specific delivery of the medication is used to establish levels of therapeutic value by the engineered nanocarriers.

Enhanced Drug Stability: Encapsulation protects delicate drugs that would be degraded by the immune system and enzyme elements.

Flexibility: Capable of delivering many different types of therapeutic agents, individual proteins, peptides, nucleic acids, and small molecules.

Challenges in Nanocarrier-Based Delivery

There are some disadvantages to nanocarriers despite the potential:

Physiological barriers: Opsonization, non-specific dispersion, and rapid clearance by the mononuclear phagocyte system (MPS) shorten their circulation time(30).

Scalability and Reproducibility: The ability to generate nanocarriers in a standardized, reproducible industrial scale that are uniform in drug loading, size, and shape remains a challenge.

Toxicity and Biocompatibility: Some nanomaterials, especially synthetic polymers and surfactants, can be toxic or create an inflammatory reaction in the long term(31).

Regulatory Barriers: The translation of research in nanomedicine to practice is also hindered by a lack of harmonised criteria used to test nanomedicine.(32).

5. Recent Advances in Nanocarrier Design

Recent advances in nanocarrier engineering have multiplied their usefulness in efficient drug delivery to the brain. The developments also attempt to minimize the toxicity along with the non-specific effects, aiming to augment specificity, stability, circulation, and penetrability across the BBB(33). Three interesting approaches to this development are pegylation and surface modification, biomimetic technology, and smart nanocarriers(34).

Smart Nanocarriers

Sensitive or smart nanocarriers are designed to respond to some internal or external cue, such as redox gradients, enzymes, heat, pH, and even external magnetic or ultrasonic fields. In the case of CNS disorders, the controlled drug release in a specific site can be activated by anomalous pH or enzyme activity in the brain tumors or inflamed tissues.(35). As an example, redox-sensitive micelles may degrade and release their therapeutic cargo in tumor microenvironments where the glutathione level is elevated, so that the therapeutic loads are directed locally where the tumor is. These nanocarriers

enhance therapeutic efficacy and reduce systemic toxicity, since they release on demand(36).

PEGylation and Surface Engineering

Biomimetic Approaches

The new technique is the use of biomimetic nanocarriers, which resemble natural biological structures. As an example, the cell membrane-coated nanoparticles (which are covered by the membrane of red blood cells, leukocytes, or even brain endothelial cells) present immunological evasion, long circulation, and homotypic targeting(30). Other strategies involve the use of virus-like particles and exosome-mimicking vesicles since the latter naturally exploit BBB-crossing pathways. These designs combine the strengths of biological systems and synthetic systems. Table 3.2

Table 3.2: Summary of Emerging Nanocarrier Strategies for BBB Targeting

Technology	Key Feature	Application
Smart Nanocarriers	Stimuli-responsive (e.g., pH, redox)	Targeted release in brain tumors
PEGylated Nanoparticles	Extended circulation time	Enhanced CNS drug bioavailability
Ligand-Targeted Carriers	Receptor-mediated transcytosis	Alzheimer's, Parkinson's therapy
Biomimetic Nanocarriers	Cell membrane coating/exosome mimicry	Immune evasion, BBB penetration
Virus-like Particles	Viral entry mimicry	Protein/RNA delivery to the brain

6. Safety, Toxicity, and Regulatory Concerns

Nanotoxicology

This science is nanotoxicology, which involves the negative effects of nanomaterials on the molecular and cellular level. Depending on composition, size, surface charge, and degradation byproducts, nanocarriers can induce oxidative stress, inflammation, immunogenicity, or cytotoxic effects. As an illustration, cationic polymeric nanoparticles (e.g., PEI) are reported to impair the cell membranes.(36), and non-degradable dendrimers could easily accumulate in the brain, resulting in neurotoxicity(30). To this is added the blood-brain barrier (BBB), which makes any perturbation, even a minor one, give rise to neuroinflammation or destruction of fragile CNS architecture. Consequently, there is a necessity for in vitro and in vivo models that examine nanocarrier-mediated changes on neural tissues and the integrity of the BBB, the reaction of glial cells, and neurobehavioral results(37).

Biodistribution and Biodegradability

The size, the shape, the surface chemistry, and the targeted ligands of nanocarriers influence their biodistribution. According to how they are uncouthly accumulated in non-target organs such as the kidneys, spleen, or liver, there is a possibility of systemic toxicity. Also, another important determinant of the safety profile of nanomaterials is their biodegradability. The optimal nanocarriers would disintegrate into nontoxic, non-obstructive compounds that allow normal physiological processes.(38). An example of such drug delivery systems is pluronic-based nanoparticles that degrade to produce lactic and glycolic acid, that is naturally metabolized by the body, thus can be used in the long term. Conversely, non-biodegradable or slowly degradable transporters might thus be hazardous in chronic situations and bioaccumulation.

Regulatory Guidelines for Brain-Targeted Nanomedicine

The regulatory organizations such as the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), or the CDSCO (India) have not yet proposed guidelines specifically aimed at CNS-targeted medicines.(38). Nevertheless, general structures point out:

- Property characterization of physicochemical properties
- Acute, chronic, reproductive, and neurotoxicology profiling
- Pharmacokinetics and pharmacodynamics information
- Risk-benefit analysis and environmental effects

The OECD and the International Organization of Standardization (ISO) have also published guidelines for risk assessment and safety testing procedures with regard to nanoparticles. Unified standards and clear regulatory processes will play a critical part in the development of the field, as CNS diseases will no longer be treated safely and effectively using nanocarriers(39).

7. Future Perspectives and Emerging Trends

Brain-targeted nanomedicine is an emerging area that creates interdisciplinary novelty capable of transforming treatment strategies. The future course would be to discard the paradigm of treatment of CNS with bulkiness, irreducible size, targeted drug delivery, drugs that do not extend their effect beyond the point of administration, leading to paling, etc.(40). Resulting in less persistence and later two is being catered to by the nanotechnology in conjunction with precision-based drug delivery, automatization of the control by the central nervous system over direct neuron connections etc.

Personalized Nanomedicine

The discussion is that the application of nanocarrier systems together with personalised medicine will change the drug delivery to the central nervous system. Metabolic signature, the permeability of the BBB, the phase of the disease, the genetic makeup of a patient, and many other patient-specific factors may significantly affect the effectiveness of a treatment.(40). Nanocarrier manipulation allows changing the surface ligand, the release kinetics, and even the combination of medications to create customized treatment plans. As an example, treatments of glioblastoma could be devised to utilize tumor-specific biomarkers, whereas nanoparticles functionalized with apolipoprotein E (ApoE) ligands could be an advantage to patients with Alzheimer's disease. Also, individualized nanomedicine offers a chance to combine therapies and diagnostics (theragnostic), which enables in situ monitoring of therapy responses.(40).

Artificial Intelligence in Nanocarrier Design

These ML and AI will increasingly become powerful tools to optimise the progression of nanocarriers. Artificial intelligence models having input parameters such as material type, drug load, and surface chemistry are capable of analysing large volumes of input data and predicting valuable nanocarrier parameters such as size, charge, and toxicity. Moreover, because of ML algorithms(41)It is now convenient to represent a model of the transport mechanisms of the BBB computationally, which improves the likelihood of finding brain bioavailability and predicting new ligand-receptor pairs. Also, AI-driven approaches accelerate drug repurposing by creating matches between known compounds and suited nanocarrier platforms and reducing the duration and cost of the development process(42).

BBB-on-a-Chip Models for Research

The complexity of the human BBB is often not recreated by the conventional in vitro and animal models. A revolutionary study platform is the development of the BBB-on-a-chip technology based on the cultivation of the endothelial cells, astrocytes, and pericytes to form the microfluidic devices capable of simulating the human BBB. On these chips, researchers can study neurotoxicity, cellular uptake, and nanocarrier trafficking in a physiologically relevant environment.(43). Dynamic surroundings of a chip predict human central nervous system (CNS) reactions better because they accurately mimic shear pressure, the flow rate, and the adherence of the barrier. Another way of bringing bench to bedside is defining how to perform individualized screening of medication through the addition of patient-derived cells to the organ-on-chip model.(41).

Conclusion

Entry of therapeutic agents into the brain remains very challenging because it has such a selective barrier as the blood-brain barrier (BBB). This chapter has discussed the role of the BBB in constructing this, together with its key role in the protection of the central nervous system, which also proves to be a barrier to the ingress of most drugs. The traditional ways of bypassing or modifying the BBB have been less useful due to their invasiveness, lack of specificity, or potential toxicity. Nevertheless, nanocarriers, e.g., A liposome, polymer nanoparticle, dendrimer, bio-mimetic system, provide a viable alternative as they help achieve targeted, regulated, and non-invasive delivery of medications across the blood-brain barrier. Examples of nanocarriers with engineered strategies that have increased brain targeting, confirmed safety, and decreased systemic toxicity include PEGylation, ligand conjugation, and stimuli-responsive designs. There are also new developments in optimization of nanocarrier formulations, such as new technologies, which are accelerating the process, including artificial intelligence. New advances are also offering more physiologically relevant preclinical testing tools, such as BBB-on-a-chip models, but there remain problems in understanding patient-specific reactivity, regulatory pathways, and chronic safety. The personalized nanomedicine with data-driven design and real-time diagnostic technologies is expected to inform future CNS treatments. The collaboration between nanotechnologists, neuroscientists, regulators, and clinicians will play an important role in translating experimental success into clinical practice as the field evolves. The complex neurological disorders, finally, may be transformed through the collective use of smart nanocarriers, predictive modeling, and personalized treatment strategies, giving hope of safer and more effective targeting of the treatment to the brain.

Acknowledgement

The authors would like to express their sincere gratitude to *Deep Science Publisher* and the editorial team of this book for their invaluable support in the final publication process and for providing the opportunity to contribute to this esteemed volume.

Conflicts of Interest

The authors declare that there are no conflicts of interest related to this work.

Funding Source

No funding was received for the preparation of this book chapter.

Author Contribution

All authors have contributed equally to the conception, preparation, and completion of this book chapter.

References

1. Li J, Long Q, Ding H, Wang Y, Luo D, Li Z, et al. Progress in the treatment of central nervous system diseases based on nanosized traditional Chinese medicine. Advanced Science. 2024;11(16):2308677.
2. Zhao M, Wang J, Zhu S, Wang M, Chen C, Wang L, et al. Mitochondrion-based organellar therapies for central nervous system diseases. Cell Communication and Signaling. 2024;22(1):487.
3. Peng Z, Hou T, Yang K, Zhang J, Mao Y-H, Hou X. Microecologics and Exercise: Targeting the Microbiota–Gut–Brain Axis for Central Nervous System Disease Intervention. Nutrients. 2025;17(11):1769.
4. Susa F, Arpicco S, Pirri CF, Limongi T. An overview on the physiopathology of the Blood–Brain barrier and the Lipid-Based nanocarriers for central nervous system delivery. Pharmaceutics. 2024;16(7):849.
5. Schirrmacher V. Brain and Immune System: Intercellular Communication During Homeostasis and Neuroimmunomodulation upon Dysfunction. International Journal of Molecular Sciences. 2025;26(14):6552.
6. Liu Q, Chen Z, Guiseppi-Elie A, Meng F, Luo L. Recent progress on nanotechnologies for enhancing blood-brain barrier permeability. Smart Molecules. 2025;3(2):e20240052.
7. Gupta U, Kosey S, Pal R. Advancements in Nanotechnology-Based Targeted Drug Delivery Systems for Glioblastoma Chemotherapy: A Comprehensive Review. Journal of Drug Delivery Science and Technology. 2025 Jun 13:107181.
8. Kirit E, Gokce C, Altun B, Yilmazer Ae. Nanotherapeutic Strategies for Overcoming the Blood–Brain Barrier: Applications in Disease Modeling and Drug Delivery. ACS Omega. 2025.
9. Castillo-González J, González-Rey E. Beyond wrecking a wall: revisiting the concept of blood–brain barrier breakdown in ischemic stroke. Neural Regeneration Research. 2025;20(7):1944-56.
10. Bassalo D, Matthews SG, Bloise E. The canine blood-brain barrier in health and disease: focus on brain protection. Veterinary Quarterly. 2025;45(1):12-32.
11. Johansson BB. Protective Barriers in the Nervous System Against Neurotoxic Agents: The Blood-Brain Barrier. In: Herken H, Hucho F, editors. Selective Neurotoxicity. Berlin, Heidelberg: Springer Berlin Heidelberg; 1992. p. 67-80.
12. Ding L, Kshirsagar P, Agrawal P, Murry DJ. Crossing the Blood–Brain Barrier: Innovations in Receptor- and Transporter-Mediated Transcytosis Strategies. Pharmaceutics. 2025;17(6):706.
13. Xiang Y, Gu Q, Liu D. Brain Endothelial Cells in Blood–Brain Barrier Regulation and Neurological Therapy. International Journal of Molecular Sciences. 2025;26(12):5843.
14. Gao J, Xia Z, Gunasekar S, Jiang C, Karp JM, Joshi N. Precision drug delivery to the central nervous system using engineered nanoparticles. Nature Reviews Materials. 2024;9(8):567-88.

15. Raut AK, Mohapatra S, Siddiqui G, Rajak SK, Sonar R, Basu S, et al. The Human Cornea: Unraveling Its Structural, Chemical, and Biochemical Complexities. Chemistry & Biodiversity. 2025;22(4):e202402224.
16. Alqudah A, Aljabali AA, Gammoh O, Tambuwala MM. Advancements in neurotherapeutics: nanoparticles overcoming the blood–brain barrier for precise CNS targeting. Journal of Nanoparticle Research. 2024;26(6):123.
17. Yasmin A, Jindal S, Monga V, Gupta GD, Goyal K. Withania coagulans: a comprehensive exploration of its botanical, phytochemical, and pharmacological properties. Medicinal Chemistry Research. 2025:1-25.
18. Chu C, Jablonska A, Gao Y, Lan X, Lesniak WG, Liang Y, et al. Hyperosmolar blood–brain barrier opening using intra-arterial injection of hyperosmotic mannitol in mice under real-time MRI guidance. Nature Protocols. 2022;17(1):76-94.
19. Helms HCC, Kristensen M, Saaby L, Fricker G, Brodin B. Drug Delivery Strategies to Overcome the Blood–Brain Barrier (BBB). In: Cader Z, Neuhaus W, editors. Physiology, Pharmacology and Pathology of the Blood-Brain Barrier. Cham: Springer International Publishing; 2022. p. 151-83.
20. Zheng X, Yang J, Hou Y, Fang Y, Wu K, Song Y, et al. Current non-invasive strategies for brain drug delivery: overcoming blood–brain barrier transport. Molecular Biology Reports. 2023;51(1):25.
21. Thomsen MS, Johnsen KB, Kucharz K, Lauritzen M, Moos T. Blood–Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles. Pharmaceutics. 2022;14(10):2237.
22. Kacemi R, Campos MG. Translational Proofs on Bee Pollen as a Source of Biopharmaceuticals for Neurodegeneration and Cancer Research: A Scoping Review and Prospective Reflections. 2024.
23. Estelrich J, Busquets MA. Magnetic Nanoparticles as Delivery Systems to Penetrate the Blood-Brain Barrier. In: Morales JO, Gaillard PJ, editors. Nanomedicines for Brain Drug Delivery. New York, NY: Springer US; 2021. p. 173-208.
24. Busquets MA, Espargaró A, Sabaté R, Estelrich J. Magnetic Nanoparticles Cross the Blood-Brain Barrier: When Physics Rises to a Challenge. Nanomaterials. 2015;5(4):2231-48.
25. Zeynalzadeh E, Khodadadi E, Khodadadi E, Ahmadian Z, Kazeminava F, Rasoulzadehzali M, et al. Navigating the neurological frontier: Macromolecular marvels in overcoming blood-brain barrier challenges for advanced drug delivery. Heliyon. 2024;10(15).
26. Sanadgol N, Abedi M, Hashemzaei M, Kamran Z, Khalseh R, Beyer C, et al. Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges. Journal of Nanobiotechnology. 2025;23(1):453.
27. Satapathy MK, Yen T-L, Jan J-S, Tang R-D, Wang J-Y, Taliyan R, et al. Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting the Brain through the BBB. Pharmaceutics. 2021;13(8):1183.
28. Zhu Y, Liu C, Pang Z. Dendrimer-Based Drug Delivery Systems for Brain Targeting. Biomolecules. 2019;9(12):790.
29. Chauhan A, Mori D, Soniwala M, Prajapati B, Shah S. Neuro-nanocarriers: redefining treatment pathways for brain disorders. BioNanoscience. 2025;15(1):78.
30. Yuan S, Hu D, Gao D, Butch CJ, Wang Y, Zheng H, et al. Recent advances in engineering cell membranes for nanomedicine delivery across the blood–brain barrier. Journal of Nanobiotechnology. 2025;23(1):493.

31. Alvin EA, Borges AV, Perini HF, da Silva MV, Silva ACA. Revolutionizing Tropical Disease Treatment: The Future of Conjugating Nanomaterials with Drugs. Journal of Exploratory Research in Pharmacology. 2024;9(4):276-86.
32. Gupta U, Kosey S, Pal R. Advancements in Nanotechnology-Based Targeted Drug Delivery Systems for Glioblastoma Chemotherapy: A Comprehensive Review. Journal of Drug Delivery Science and Technology. 2025 Jun 13:107181.
33. Jahandar-Lashaki S, Farajnia S, Faraji-Barhagh A, Hosseini Z, Bakhtiyari N, Rahbarnia L. Phage display as a medium for target therapy-based drug discovery, review and update. Molecular Biotechnology. 2024:1-24.
34. Tiwari A, Goswami S, Joshi M, Gandhi S, Soni P, Tekade M, et al. PEGylation as a Tool to Alter Immunological Properties of Nanocarriers. In: Tekade RK, Jain NK, editors. PEGylated Nanocarriers in Medicine and Pharmacy. Singapore: Springer Nature Singapore; 2025. p. 171-93.
35. Behera A, Nayak AK, Mohapatra RK, Rabaan AA. Smart Micro-and Nanomaterials for Pharmaceutical Applications: CRC Press; 2024.
36. Andoy NMO, Patel M, Lui CLJ, Sullan RMA. Immobilization of Polyethyleneimine (PEI) on Flat Surfaces and Nanoparticles Affects Its Ability to Disrupt Bacterial Membranes. Microorganisms. 2021;9(10):2176.
37. Rodrigues RO, Shin S-R, Bañobre-López M. Brain-on-a-chip: an emerging platform for studying the nanotechnology-biology interface for neurodegenerative disorders. Journal of Nanobiotechnology. 2024;22(1):573.
38. Hassan D, Sani A, Medina DI. Limitations of Nanocarriers: Such as Cell and Tissue Toxicity, Genotoxicity, and Scale-Up of Nanomaterials. In: Khan FA, editor. Nano Drug Delivery for Cancer Therapy: Principles and Practices. Singapore: Springer Nature Singapore; 2023. p. 149-71.
39. Liu J, Wang T, Dong J, Lu Y. The blood–brain barriers: novel nanocarriers for central nervous system diseases. Journal of Nanobiotechnology. 2025;23(1):146.
40. Senanayake D, Yapa P, Dabare S, Munaweera I. Precision targeting of the CNS: recent progress in brain-directed nanodrug delivery. RSC Advances. 2025;15(32):25910-28.
41. Chen X, Liu C, Muok L, Zeng C, Li Y. Dynamic 3D On-Chip BBB Model Design, Development, and Applications in Neurological Diseases. Cells. 2021;10(11):3183.
42. Tomitaka A, Vashist A, Kolishetti N, Nair M. Machine learning assisted-nanomedicine using magnetic nanoparticles for central nervous system diseases. Nanoscale Advances. 2023;5(17):4354-67.
43. Peng B, Hao S, Tong Z, Bai H, Pan S, Lim K-L, et al. Blood–brain barrier (BBB)-on-a-chip: a promising breakthrough in brain disease research. Lab on a Chip. 2022;22(19):3579-602.